Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
IPO Year:
Exchange: NASDAQ
Website: windtreetx.com
8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
EFFECT - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
EFFECT - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
424B5 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
424B5 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
DEF 14A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
S-1 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
S-3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
PRE 14A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
WARRINGTON, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company's first SEISMiC Ph
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates. "The second quarter of 2024 was marked with significant progress with our lead asset, istaroxime in development for the treatment of cardiogenic shock. We expect the istaroxime Phase 2 SEISMiC Extension study to complete enrollment in the next few weeks and we plan to report topline data by the end of the third quarter of 2024. We are also sup
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of directors, effective August 13, 2024, which include the appointment of Saundra Pelletier and Jed Latkin as two new independent directors with significant public company director and executive leadership. Joining the Windtree board is Saundra Pelletier, who has served as the Interim Chair since late 2021 and as Chief Executive Officer, President and Executive Director since early 2015 of Evofem Bioscien
WARRINGTON, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced an update of istaroxime in both clinical and business development. Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function. It has been studied in three positive Phase 2 trials enrolling patients with acute heart failure (AHF) and early cardiogenic shock. In line
$12.9 Million Transaction Includes Approximately $3.4 Million of New Fundingand a $9.5 Million Full Cancellation of Outstanding Senior Notesand Extinguishment of Series B Preferred Shares The Company Also Established a $35 Million Equity Line of Credit WARRINGTON, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the closing of a private placement of (i) 16,099 shares of the Company's Series C Convertible Preferred Stock, $0.001 par value (the "Series C Preferred Stock"), and (ii) war
WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Company was previously notified by Nasdaq on January 22, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed t
WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ:WINT) ("Windtree" or the "Company"), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company's Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time on April 19, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol "WINT" on April 22, 2024. At such time, the
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates. "The end of 2023 and the past few months have been very productive at Windtree as we advanced clinical programs, executed a license for cardiovascular assets, took actions to strengthen our balance sheet and, most recently, acquired a novel oncology preclinical atypical protein kinase C iota inhibitor (aPKCi inhi
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. ("Varian") to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi). The Company also completed a $1.5 million convertible note bridge financing. The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases. The asset platform includes two formulations: VAR-101 (topical) and VAR-102 (o
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company's cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the collaboration. The scientific collaboration includes the Company's lead product candidate istaroxime and the next generation compounds called SERCA2a activators. One of istaroxime's mechanisms o
Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates. "The second quarter of 2024 was marked with significant progress with our lead asset, istaroxime in development for the treatment of cardiogenic shock. We expect the istaroxime Phase 2 SEISMiC Extension study to complete enrollment in the next few weeks and we plan to report topline data by the end of the third quarter of 2024. We are also sup
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of directors, effective August 13, 2024, which include the appointment of Saundra Pelletier and Jed Latkin as two new independent directors with significant public company director and executive leadership. Joining the Windtree board is Saundra Pelletier, who has served as the Interim Chair since late 2021 and as Chief Executive Officer, President and Executive Director since early 2015 of Evofem Bioscien
WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors. Dr. Strobeck has more than 20 years of experience in operations, business development, capital raising and M&A and has a track record of success creating and building value for emerging and public biotechnology and life sciences companies. Currently, Dr. Strobeck is President and CEO, and a Member of the Board, at Rockwell Medical, a publicly held healthcare company that devel
WARRINGTON, Pa., July 1, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Diane Carman, Esq. as Senior Vice President and General Counsel, reporting to Craig Fraser, President and Chief Executive Officer. Ms. Carman brings over two decades of successful experience working in the life sciences and other highly regulated industries. She has built the legal and compliance infrastruc
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced an update of istaroxime in both clinical and business development. Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function. It has been studied in three positive Phase 2 trials enrolling patients with acute heart failure (AHF) and early cardiogenic shock.
The Company has the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase, up to the lesser of (i) $35 million of newly issued shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and (ii) the Exchange Cap.
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Company was previously notified by Nasdaq on January 22, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30
Windtree Therapeutics's (NYSE:WINT) short percent of float has risen 30.3% since its last report. The company recently reported that it has 39 thousand shares sold short, which is 0.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short int
Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading lower by 20% to $0.32 during Thursday’s session after the company announced it approved a 1-for-18 reverse stock split of its common stock. This measure, effective April 19, 2024, aims to increase the market price per share, ensuring compliance with Nasdaq’s minimum bid price requirement. Each 18 shares will be converted into 1 share without altering the stock’s par value. The split affects all shareholders proportionally and does not change their ownership percentage, with fractional shares rounded up. See Also: Netflix Stock Is In The Spotlight Thursday: What’s Going On? Should I Sell My WINT Stock? Whether to sell
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results. The company reported quarterly adjusted earnings of 75 cents per share which beat the analyst consensus estimate of 62 cents and represented a 167.86% increase from the same period last year. Quarterly sales clocked in at $2.96 billion which beat the analyst consensus estimate of $2.94 billion and is a 39.58% increase over sales of $2.12 billion from the same quarter last year, according to data from Benzinga Pro. Las Vegas Sands shares dipped 6.8% to $46.81 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers AGBA
Windtree Therapeutics (NASDAQ:WINT) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.94) by 1.06 percent.
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. ("Varian") to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi). The Company also completed a $1.5 million convertible note bridge financing. The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases. The asset platform includes two formulations: VAR-101 (topical) and VAR-102 (o
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours The study also met several key secondary endpoints associated with improving cardiac function Investor conference call and webcast to be held today, Monday May 23 at 4:30 pm EDT WARRINGTON, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today presented data from its positive Phase 2 study of istaroxim
WARRINGTON, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced management will host a conference call and webcast to discuss its istaroxime Phase 2 study in early cardiogenic shock patients following the late-breaker presentation of the data at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain on May 23, 2022. The Company previously announced a positive topline result from the trial and explained that further details were under embargo due to the acceptance of the late-breaker presentation
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced a late-breaker presentation at the upcoming European Society of Cardiology Heart Failure Conference taking place on May 21-24, 2022 in Madrid, Spain. Late-Breaking Science sessions are innovative and provide the latest breakthroughs in clinical science. These sessions provide notable exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field. The presentatio
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13D/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13D/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13D/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)
SC 13D/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)